CUTR News and Press, Cutera Inc. From 07/13/22

The First and Only Device in North America Cleared for the Treatment of Mild, Moderate and Severe Acne AviClear has been Proven Safe and Effective Through an Extensive Clinical Trial Provides Long-term Resolution of Acne Across All Skin Types Cutera, Inc....

Cutera has received an FDA clearance for the first and only laser-based acne treatment representing a significant market opportunity. The company last reported its Q1 results in May, highlighted by solid sales momentum from its existing skin revitalization and body sculpting products ...

Cutera Aims to Help Acne Sufferers Be Fully Present in Their Lives with the National Launch of AviClear™ Ninety percent of moderate to severe acne sufferers said having acne-free skin would dramatically change the way they live their life, according to a new survey re...

Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announced the pricing of $210 million aggregate principal amount of 2.25% convertible senior notes due 2028 (the “notes”) in a private placement to persons reasonably believed to ...

Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announced that it intends to offer, subject to market conditions and other factors, $200 million aggregate principal amount of convertible senior notes due 2028 (the “notes”) in a...

Image source: The Motley Fool. Cutera (NASDAQ: CUTR) Q1 2022 Earnings Call May 10, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Cutera (CUTR) Q1 2022 Earnings Call Transcript

Cutera, Inc. (CUTR) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Dave Mowry – Chief Executive Officer Rohan Seth – Chief Financial Officer Conference Call Participants Jon Block – Stifel Chris Cooley – Stephens Louise Chen – ...

Cutera  press release (NASDAQ:CUTR): Q1 GAAP EPS of -$0.84 misses by $0.63. Revenue of $58M (+16.8% Y/Y) beats by $0.74M. For further details see: Cutera  GAAP EPS of -$0.84 misses by $0.63, revenue of $58M beats by $0.74M

Delivers 17% revenue growth as reported and 21% on a constant currency basis AviClear ™ investments were accelerated in 1Q22 ahead of FDA device clearance New ERP system launched Company reiterates full-year guidance at current exchange...

CUTERA, INC. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of dermatology solutions, today announced that clinical data related to AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne; was presented during the...